联环药业
(600513)
| 流通市值：26.01亿 | | | 总市值：26.01亿 |
| 流通股本：2.85亿 | | | 总股本：2.85亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 627,705,511.57 | 2,160,457,160.63 | 1,644,578,576.25 | 1,126,339,878.99 |
| 营业收入 | 627,705,511.57 | 2,160,457,160.63 | 1,644,578,576.25 | 1,126,339,878.99 |
| 二、营业总成本 | 587,869,188.52 | 2,050,251,134.72 | 1,516,612,393.88 | 1,035,476,886.36 |
| 营业成本 | 367,224,522.89 | 1,093,743,600.55 | 824,022,908.65 | 552,203,143.67 |
| 税金及附加 | 4,707,131.63 | 19,736,310.55 | 14,807,669.41 | 10,554,308.38 |
| 销售费用 | 145,209,909.62 | 613,910,294.64 | 459,172,224.37 | 320,984,673.4 |
| 管理费用 | 41,387,718.67 | 144,812,545.38 | 106,058,391.31 | 72,589,400.93 |
| 研发费用 | 22,273,387.47 | 154,589,086.68 | 94,317,179.81 | 67,579,468.48 |
| 财务费用 | 7,066,518.24 | 23,459,296.92 | 18,234,020.33 | 11,565,891.5 |
| 其中:利息费用 | 7,202,674.9 | 24,951,127.75 | 18,910,310.58 | 12,123,272.4 |
| 其中:利息收入 | 108,149.22 | 679,073.4 | 582,086.05 | 447,127.31 |
| 加:投资收益 | -1,523,863.03 | -10,586,429.4 | -5,619,978.64 | -4,897,063.55 |
| 资产处置收益 | - | 35,029,139.47 | -700 | - |
| 资产减值损失(新) | -453,642.02 | -5,211,934.12 | -387,662.65 | -55,106.51 |
| 信用减值损失(新) | 1,149,040.1 | -8,145,010.15 | -4,976,129.62 | -2,553,197.84 |
| 其他收益 | 2,269,307.26 | 9,727,230.56 | 5,501,078.08 | 3,894,680.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 41,277,165.36 | 131,019,022.27 | 122,482,789.54 | 87,252,305.63 |
| 加:营业外收入 | 261,820.05 | 27,508.81 | 26,096.34 | 25,000 |
| 减:营业外支出 | 80,316.43 | 618,747.83 | 529,389.23 | 208,742.96 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 41,458,668.98 | 130,427,783.25 | 121,979,496.65 | 87,068,562.67 |
| 减:所得税费用 | 14,064,770.91 | 24,013,037.91 | 14,440,492.06 | 14,387,483.08 |
| 六、净利润 | 27,393,898.07 | 106,414,745.34 | 107,539,004.59 | 72,681,079.59 |
| 持续经营净利润 | 27,393,898.07 | 106,414,745.34 | 107,539,004.59 | 72,681,079.59 |
| 归属于母公司股东的净利润 | 23,059,579.59 | 84,159,987.05 | 92,699,157.34 | 62,887,897.87 |
| 少数股东损益 | 4,334,318.48 | 22,254,758.29 | 14,839,847.25 | 9,793,181.72 |
| (一)基本每股收益 | 0.08 | 0.29 | 0.32 | 0.22 |
| (二)稀释每股收益 | 0.08 | 0.29 | 0.32 | 0.22 |
| 八、其他综合收益 | -93,937.21 | 78,920.88 | -73,049.96 | -43,210.19 |
| 归属于母公司股东的其他综合收益 | -93,937.21 | 78,920.88 | -73,049.96 | -43,210.19 |
| 九、综合收益总额 | 27,299,960.86 | 106,493,666.22 | 107,465,954.63 | 72,637,869.4 |
| 归属于母公司股东的综合收益总额 | 22,965,642.38 | 84,238,907.93 | 92,626,107.38 | 62,844,687.68 |
| 归属于少数股东的综合收益总额 | 4,334,318.48 | 22,254,758.29 | 14,839,847.25 | 9,793,181.72 |
| 公告日期 | 2025-04-30 | 2025-04-18 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |